Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer - Poll - MDSpire

Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer

  • By

  • Hailin Zhu

  • Wang Yi

  • Yujie Wu

  • Rong Li

  • Boxuan Zhou

  • June 16, 2026

  • 0 min

Share

Original Source(s)

Immune–tumor cell ligand–receptor axes driving metabolic reprogramming and therapeutic resistance in cancer

  • by Hailin Zhu, Wang Yi, Yujie Wu, Rong Li, Boxuan Zhou

  • June 16, 2026

Related Content

Primary cutaneous adenoid cystic carcinoma of the right forearm: a case report and dermoscopic features

Correction: The efficacy of angiogenesis inhibitors combined with chemotherapy in advanced breast cancer: a systematic review and meta-analysis

Tissue-Resident NK Cells Slow Solid Tumor Growth in Mice

The study points to a possible off-the-shelf cell therapy for solid tumors

  • June 16, 2026

  • 3 min